T-Cell Surface Antigen T4/Leu-3
Graft Versus Host Disease
Explore 34 assets in Graft Versus Host Disease →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Masonic Cancer Center, University of Minnesota
Modality
protein_peptide
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00725062CT.gov Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Graft Versus Host Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Surface Antigen T4/Leu-3 (this asset) | Masonic Cancer Center, University of Minnesota | P1 | D · 30 |
| Cyclophosphamide | City of Hope Medical Center | P4 | BBB |
| Busulfanum | City of Hope Medical Center | P4 | BBB |
| Thiotepa | Memorial Sloan Kettering Cancer Center | P4 | BBB |
| Nivestim | City of Hope Medical Center | P4 | BBB |
| Cyclosporin A | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Ruxolitinib | Jonathan Brammer | P4 | BB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Assistance Publique - Hôpitaux de Paris | P4 | BB |
| Tacrolimus | City of Hope Medical Center | P3 | BB |
+41 more in the Graft Versus Host Disease cohort
Other indications for T-Cell Surface Antigen T4/Leu-3
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Non-Hodgkin Lymphoma | — | P2 | C · 36 |
| Plasma Cell Myeloma | — | P1 | D · 30 |
| Hemoglobinopathy | — | P1 | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. T-Cell Surface Antigen T4/Leu-3 in Graft Versus Host Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/t-cell-surface-antigen-t4leu-3-graft-versus-host-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →